Data Sheet 1_An anoikis-related gene signature predicts prognosis and immunotherapy respon

A six-gene prognostic signature stratifies triple-negative breast cancer patients into high- and low-risk groups with significant differences in overall survival. Yan Chen published this research document on figshare in May 2026 under a CC-BY-4.0 license. The signature correlates with the immunogenomic landscape and predicts responses to targeted therapy and immunotherapy.

Use Cases

• Predicting patient prognosis based on the six-gene anoikis-related signature.
• Assessing immunotherapy response potential based on correlations with the immunogenomic landscape.
• Identifying therapeutic targets, such as CCAR2, for anoikis resistance and immune evasion.
• Developing clinical nomograms for patient stratification using the prognostic signature.

Strengths

• The signature is based on six anoikis-related genes, providing a focused prognostic model.
• The research includes validation via RT-qPCR, immunohistochemistry, Kaplan-Meier analysis, and multivariate Cox regression.
• The document is 8.3 MB and includes detailed methodological and results sections.

Limitations

• The underlying data columns and row counts are unknown, limiting suitability assessment.
• The dataset is a single DOCX file, which may require manual extraction of tabular data.
• Freshness should be verified as the last update is projected for 2026.

Provenance

Source

figshare

Collection Method

Research analysis involving Cox regression, random survival forest analysis, and in vitro functional experiments.

Freshness

Last updated 2026-05-20 05:47:37; freshness should be verified.